Survodutide 10 mg

DRAGON PHARMA SURVODUTIDE

Dragon Pharma Survodutide 10 mg represents the next evolution in peptide-based body recomposition, engineered for the athlete who demands more than simple appetite suppression. As a novel dual agonist targeting both the Glucagon-Like Peptide-1 (GLP-1) and Glucagon (GCGR) receptors, Survodutide delivers a powerful two-pronged attack on stubborn body fat. For bodybuilders in a cutting phase, fitness enthusiasts facing a plateau, or any individual seeking a sophisticated metabolic tool, this peptide offers a distinct advantage. It not only promotes profound satiety and reduced caloric intake—like its GLP-1 cousins—but also uniquely increases energy expenditure by stimulating the liver to burn more calories, a property driven by its glucagon receptor activity. This dual mechanism can lead to superior fat loss while potentially offering a more favorable muscle-to-fat loss ratio compared to single-mechanism agents. Dragon Pharma's precise 10 mg formulation, verified by independent lab testing, ensures you receive a potent, research-grade compound designed to push the boundaries of what's possible in metabolic optimization and physique refinement.

DRUG COMPOSITION

Each 2 mL vial contains 10 mg of highly purified Survodutide (also known as BI 456906). Survodutide is a synthetic, acylated peptide designed to act as a dual agonist. Its structure is engineered to simultaneously activate both the GLP-1 receptor and the Glucagon receptor with high specificity. The peptide is presented as a sterile, white lyophilized powder without buffers or preservatives, requiring reconstitution before use to ensure optimal stability and bioavailability.

PHARMACEUTICAL FORM

Sterile, white to off-white lyophilized (freeze-dried) powder in a multi-dose 2 mL glass vial. The vial is sealed with a bromobutyl rubber stopper and an aluminum flip-off cap to ensure sterility and tamper evidence. The product must be reconstituted with Bacteriostatic Water prior to subcutaneous injection.

PHARMACEUTICAL GROUP AND ATC CODE

Survodutide belongs to the pharmacological class of incretin mimetics and dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonists. Its primary actions align with drugs used for weight management and type 2 diabetes. Its anticipated Anatomical Therapeutic Chemical (ATC) classification would be under A10BX - Other drugs used in diabetes and potentially A08AB - Centrally acting antiobesity products, though it is not yet FDA-approved for these uses.

PHARMACOLOGICAL PROPERTIES

Survodutide's efficacy stems from its innovative dual-receptor agonism, creating a synergistic metabolic effect:

• GLP-1 Receptor Agonism (The "Brake"):
  • Appetite Suppression: Activates receptors in the brain's appetite centers (hypothalamus and brainstem), promoting profound and sustained feelings of fullness (satiety) and reducing hunger signals.
  • Slowed Gastric Emptying: Delays the rate at which food leaves the stomach, leading to prolonged nutrient absorption and reduced post-meal hunger pangs.
  • Glucose-Dependent Insulin Secretion: Enhances insulin release from the pancreas only when blood glucose is high, improving glycemic control without risk of hypoglycemia.
• Glucagon Receptor Agonism (The "Accelerator"):
  • Increased Energy Expenditure: Stimulates the liver to increase gluconeogenesis and overall energy production, effectively raising the body's basal metabolic rate (BMR). This creates a sustained calorie-burning effect, even at rest.
  • Enhanced Lipolysis: Promotes the breakdown of stored fat (triglycerides) into free fatty acids for use as fuel.
  • Potential Muscle Preservation: Emerging research suggests that the glucagon component, by providing an alternative energy substrate (from fat), may help spare lean muscle tissue during caloric restriction, a critical advantage for athletes.

The combination results in a "calories in vs. calories out" advantage from both sides of the equation: reducing intake while increasing output, making it exceptionally effective for significant fat loss.

THERAPEUTICAL INDICATIONS

For research and body composition optimization, Dragon Pharma Survodutide 10 mg is indicated for:

• Advanced Body Recomposition: Achieving significant reductions in body fat percentage while aiming to maximize the preservation of lean muscle mass, crucial for bodybuilders and athletes.
• Breaking Weight Loss Plateaus: Overcoming stubborn stalls in fat loss where diet and exercise alone are no longer effective, especially for those with metabolic adaptation.
• Pre-Contest Cutting Phases: As a potent tool in the final weeks before a competition to shed subcutaneous fat and achieve extreme leanness with controlled appetite.
• Management of Metabolic Health Markers: Supporting improvements in insulin sensitivity, blood glucose levels, and lipid profiles as part of a comprehensive health protocol.
• Long-Term Weight Management Strategy: For individuals seeking a sustainable pharmacological aid to maintain a lower body weight after significant loss.

DOSES AND METHOD OF ADMINISTRATION

Reconstitution: Add 1-2 mL of Bacteriostatic Water to the 10 mg vial. Gently swirl (do not shake) until the powder is fully dissolved. This yields a concentration of 5-10 mg/mL.

Titration Protocol (Crucial): To minimize gastrointestinal side effects, a gradual dose escalation is mandatory.

• Weeks 1-2: 0.5 mg (500 mcg) administered via subcutaneous injection once per week.
• Weeks 3-4: Increase to 1.0 mg (1000 mcg) once per week.
• Weeks 5-6: Increase to 2.0 mg (2000 mcg) once per week.
• Weeks 7+ (Maintenance): The effective dose for significant fat loss in clinical trials is typically 4.8 mg to 6.0 mg once weekly. Some users may titrate up to these levels based on tolerance and goals.

Cycle Length: Given its mechanism for chronic weight management, cycles are typically long-term, ranging from 12 to 24 weeks (3 to 6 months). Longer use may be employed for sustained management.

Administration: Administered via subcutaneous injection into the abdomen, thigh, or upper arm. Rotate injection sites weekly. The long half-life allows for convenient once-weekly dosing. Strict aseptic technique is essential.

CYCLE/STACKING

Survodutide's unique profile allows it to be the centerpiece of sophisticated cutting and recomposition stacks.

• For Maximum Muscle Preservation During a Cut: Stack with a selective androgen receptor modulator (SARM) like S4 (Andarine) or LGD 4033 to provide a strong anabolic signal to muscle tissue, counteracting any potential catabolism from a severe calorie deficit.
• In a Metabolic Power Stack: Combine with the PPARδ agonist GW501516 (Cardarine) to further enhance fat oxidation, improve lipid profiles, and boost endurance, allowing for more intense fasted cardio sessions.
• During a "Mini-Cut" or Aggressive Fat Loss Phase: Use alongside a thyroid hormone like T3 (Cytomel) and a beta-2 agonist like Salbutamol for a multi-mechanism approach that aggressively targets metabolism, thermogenesis, and appetite.
• For Gut Health & Nutrient Partitioning: Pair with the gut-healing peptide BPC 157 to mitigate any GI discomfort.
• Post-Bulk "Clean-Up" Stack: Use after a mass-gaining phase with compounds like Testabol 400 or Deca 300 to efficiently shed the gained fat while retaining the new muscle, facilitated by the sustained anabolic environment.

POST CYCLE THERAPY (PCT)

Survodutide does not suppress the hypothalamic-pituitary-testicular axis (HPTA) and therefore does not require traditional SERM-based PCT for testosterone recovery. However, a strategic "PCT" for metabolic health is advisable. After a long cycle of significant caloric restriction aided by Survodutide, it is crucial to:

1. Gradually Taper the Dose: Do not stop abruptly. Over 2-4 weeks, gradually reduce the weekly dose to allow your natural hunger signals and metabolism to readjust.
2. Reverse Diet: Systematically increase caloric intake post-cycle, focusing on protein and whole foods, to restore metabolic rate without rapid fat regain.
3. Supportive Supplements: Consider incorporating compounds that support metabolic flexibility and appetite regulation during the transition, such as Testagen for hormonal optimization.

SIDE EFFECTS

The most common side effects are gastrointestinal and dose-dependent, often diminishing with continued use and proper titration.

• Very Common (>10%): Nausea, vomiting, diarrhea, constipation, abdominal pain/discomfort.
• Common (1-10%): Decreased appetite, dyspepsia (indigestion), gastroesophageal reflux, fatigue, headache, injection site reactions (redness, itching).
• Uncommon (<1%): Gallbladder issues (e.g., cholelithiasis), acute pancreatitis (very rare but serious), hypoglycemia (especially if used with other diabetes medications).
• Muscle Mass: Unlike some GLP-1 agonists, the glucagon activity in Survodutide may offer some muscle-sparing benefit, but significant caloric deficits can still lead to muscle loss if protein intake and training are not optimized.

There are no androgenic, estrogenic, or hepatotoxic effects directly associated with Survodutide.

CONTRAINDICATIONS

Contraindications include:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• History of severe hypersensitivity reaction to Survodutide or any of the excipients.
• Patients with severe gastrointestinal disease (e.g., gastroparesis).
• History of pancreatitis.
• Pregnancy and breastfeeding (due to lack of safety data).

OVERDOSE

In the event of overdose, severe and persistent nausea, vomiting, and diarrhea leading to dehydration are the most likely consequences. There is no specific antidote. Treatment should be symptomatic and supportive, focusing on maintaining hydration and electrolyte balance. In cases of severe dehydration, medical attention may be required. Given the long half-life, effects may persist for several days.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

This product is for research purposes only. It is not approved for human consumption. Key warnings include:

• Thyroid C-Cell Tumor Risk: Rodent studies with GLP-1 receptor agonists have shown a risk of thyroid C-cell tumors. The relevance to humans is unknown but contraindicates use in those at risk.
• Pancreatitis: Discontinue use permanently if pancreatitis is suspected (severe, persistent abdominal pain).
• Hypoglycemia: Risk increases when used with insulin or insulin secretagogues.
• Acute Kidney Injury: Severe GI side effects can lead to dehydration and renal impairment. Maintain adequate fluid intake.
• Gallbladder Disease: May increase the risk of cholelithiasis and cholecystitis.
• Suicidal Behavior and Ideation: Monitor for new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior.

INTERACTIONS WITH OTHER DRUGS

• Insulin and Insulin Secretagogues (e.g., Sulfonylureas): Increases the risk of hypoglycemia. Dose reductions of these agents may be necessary.
• Oral Medications: Due to slowed gastric emptying, Survodutide may impact the absorption rate of other orally administered drugs. Monitor effects of medications with a narrow therapeutic window (e.g., warfarin).
• Other Appetite Suppressants or Metabolic Agents: Concomitant use may have additive effects on weight loss and side effects. Use with caution when stacking with compounds like Clenbuterol or T3.

PRESENTATION, PACKAGING

Dragon Pharma Survodutide 10 mg is presented in professional, discreet packaging. Each box contains one 2 mL clear glass vial. The vial is sealed with a medical-grade rubber stopper and a tamper-evident aluminum flip-off cap. The label clearly displays the Dragon Pharma logo, product name "Survodutide," strength "10 mg," batch number, expiration date, and storage instructions. The packaging ensures protection from light and moisture.

STORAGE

• Before Reconstitution: Store the unopened vial in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep in the original carton to protect from light. For short-term travel (under 7 days), it may be kept at room temperature (not exceeding 30°C/86°F).
• After Reconstitution: The reconstituted solution should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F). It is stable for up to 28 days once reconstituted and refrigerated. Do not freeze the reconstituted solution. Discard if cloudy or contains particles.

DELIVERY TO THE USA

We guarantee fast, secure, and discreet shipping to all 50 states. Orders are processed within 24-48 hours on business days and shipped in plain, unmarked packaging with no external indication of contents. We use reliable carriers and provide tracking information upon shipment. Delivery within the continental USA typically takes 3-7 business days. All transactions are secured with industry-standard SSL encryption.

LEGAL STATUS

Survodutide is an investigational peptide and is not approved by the U.S. Food and Drug Administration (FDA) for any use. It is not a controlled substance. This product is sold strictly for laboratory research purposes as a chemical or biological reagent. The buyer assumes all responsibility for understanding and complying with all applicable local, state, and federal laws regarding the purchase, possession, and use of this material.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• U.S. National Library of Medicine - Clinical trial record detailing the study design and outcomes for Survodutide in obesity (BI 456906).
• NIH/PubMed - Review article on dual GLP-1/glucagon receptor agonists: mechanisms and therapeutic potential in metabolic disease.

PROFILE

• Chemical name: Survodutide (BI 456906)
• Chemical formula: C₂₂₅H₃₄₈N₆₀O₆₈
• Percentage of anabolic activity: 0% (Non-anabolic; may have muscle-sparing effects indirectly via energy substrate provision).
• Percentage of androgenic activity: 0% (Non-androgenic).
• Active half life: Approximately 120-150 hours (~5-6 days), supporting once-weekly dosing.
• Recommended dosage: Titrate from 0.5 mg to 4.8-6.0 mg once weekly subcutaneously.
• Acne: None.
• Bloating (water retention): None; may cause gastrointestinal distension from slowed digestion.
• HBR (High Blood Pressure): No direct effect; may improve BP due to weight loss.
• Hepatic toxicity: None reported in clinical trials.
• Aromatization: Does not aromatize.

Third Party Lab Test

2024-09-13

View Result

9.68 mg